Rome, Italy
Research view
Ovarian cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- BRCA1 20
- BRCA2 13
- PARP 27
- TP53 6
- PD-1 12
- AKT 2
- HER2 16
- PD-L1 7
- PI3K 3
- STAT3 1
- mTOR 0
- VEGF 6
- KRAS 6
- EGFR 3
- PTEN 2
- CTNNB1 0
- FAK 1
- MAPK 0
- MYC 0
- NRF2 0
- CTLA-4 6
- ERK 1
- JAK 0
- STING 0
- GPX4 0
- HIF-1 0
- MEK 1
- TROP2 4
- PALB2 5
- B7-H3 7
- CDK4/6 4
- ATM 1
- CD47 0
- IL-6 0
- EZH2 1
- JNK 0
- PIK3CA 3
- YAP 0
- BCL-2 0
- BRAF 4
- CXCR4 0
- HDAC 0
- PPAR 0
- AMPK 0
- ARID1A 3
- AXL 1
- COX-2 2
- NMDA 0
- TIGIT 0
- AR 0
- CD40 1
- HER3 1
- HMGB1 0
- KEAP1 1
- METTL3 0
- RAS 0
- TLR4 0
- FGFR 0
- PINK1 0
- PKM2 0
EU-13 is a filter, not a ranking: it only narrows the list.
Rochester, United States
Milan, Italy
Philadelphia, United States
Los Angeles, United States
London, United Kingdom
Berlin, Germany
Columbus, United States
Baltimore, United States
Stockholm, Sweden
Melbourne, Australia
Birmingham, United States
Chapel Hill, United States
Atlanta, United States
Evanston, United States
Oklahoma City, United States
Columbus, United States
Goyang-si, South Korea
Hangzhou, China
Cleveland, United States
Guangzhou, China
Amsterdam, Netherlands
Essen, Germany
Salt Lake City, United States
24 of 40+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Withdrawn
“never opened”Registry text, quoted unchanged. Source
Terminated
“The Sponsor has achieved its objectives.”Registry text, quoted unchanged. Source
Withdrawn
“Sponsor terminated due to Olaparib losing patent”Registry text, quoted unchanged. Source
Terminated
Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)
“Low accrual rate”Registry text, quoted unchanged. Source
Terminated
“Treatment availability issue: The manufacturer of AsiDNA™ decided to cease production to develop an improved version, and the contract ensuring access to this molecule has expired.”Registry text, quoted unchanged. Source
Withdrawn
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
“Investigator Discretion”Registry text, quoted unchanged. Source
Terminated
“Terminated due to safety”Registry text, quoted unchanged. Source
Terminated
“There was no anticipated benefit of the experimental combination as tested over available standard therapies; therefore Sponsor has decided to terminate the investigation.”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 48
- Organoids 19
- Mendelian Randomization Analysis 28
- CRISPR-Cas Systems 15
- Gene Expression Profiling 126
- Sequence Analysis, RNA 11
- Whole Genome Sequencing 6
- Exome Sequencing 11
- Proteomics 62
- Metabolomics 17
- Mass Spectrometry 6
- Flow Cytometry 26
- Immunohistochemistry 95
- Liquid Biopsy 15
- Circulating Tumor DNA 13
- Xenograft Model Antitumor Assays 234
- Positron-Emission Tomography 9
- Magnetic Resonance Imaging 56
- Machine Learning 58
- Deep Learning 35
- Cohort Studies 104
- Genome-Wide Association Study 25
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.